Staphylococcus aureus is a bacteria commonly found on nose or skin of healthy people. MRSA i.e., methicillin-resistant staphylococcus aureus, is thus a type of staphylococcus aureus that is resistant to beta-lactam antibiotic called methicillin. MRSA strains do not respond to methicillin treatment. Around 1% of the population carrying staphylococcus aureus on their nose or skin are infected by MRSA. The infection causes skin and tissue infection, and is transmitted by direct skin-to-skin contact.



Scope of the Report:

This report focuses on the MRSA Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Methicillin-resistant Staphylococcus aureus (MRSA) is a skin infection that occurs mostly in hospitals and healthcare facilities. It is treated with commonly-used antibiotics and is highly contagious. This infection is difficult to treat because it is sometimes resistant to commonly-used antibiotics such as methicillin. As per this market research report, the aging people are highly susceptible to MRSA infections, especially in the hospital environment as their weak immune system makes them easily prone to diseases and infections.

The worldwide market for MRSA Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new study.



Market Segment by Manufacturers, this report covers

Allergan

Merck

Pfizer

Theravance Biopharma

Absynth Biologics

AmpliPhi Biosciences

AstraZeneca

Basilea Pharmaceutica

Baxter

Cellceutix

Cempra

CrystalGenomics

Debiopharm

Galapagos

GSK

KYORIN Pharmaceutical

Lytix Biopharma

Melinta Therapeutics

Nabriva Therapeutics

NovaDigm Therapeutics



Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)



Market Segment by Type, covers

Tetracycline

Folate antagonist

Cephalosporin

Lipopeptides

Oxazolidinone

Lipoglycopeptide



Market Segment by Applications, can be divided into

Hospital

Research

Clinic

Other



There are 15 Chapters to deeply display the global MRSA Drugs market.

Chapter 1, to describe MRSA Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of MRSA Drugs, with sales, revenue, and price of MRSA Drugs, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of MRSA Drugs, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, MRSA Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe MRSA Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source